Keywords: Pfizer, Zelboraf, Vemurafenib, Metastatic melanoma, USA, FDA, Companion diagnsotic
Roche’s Zelboraf and companion diagnostic for late-stage melanoma cleared in USA
Article | 18 August 2011
Swiss drug major Roche (ROG: SIX) yesterday received US Food and Drug Administration approval for Zelboraf (vemurafenib) in the treatment ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
